Abstract
Background: Intravenous route of drug administration has maximum bioavailability, which shows 100% of the drug reaches blood circulation, whereas the oral administration of drugs, are readily undergoing pre-systemic metabolism, which means the poor bioavailability of the drug and limited amount of drug reaches the target site.
Introduction: Bioenhancers are substances having medicinal entities which enhance the bioavailability and efficacy of the active constituents of drugs. The enhanced bioavailability of drugs may lead to dose reduction, which may further reduce the cost and undesired side effects associated with the drugs.
Methods: The solid lipid nanoparticles (SLNs) loaded with ketoprofen made from carnauba wax and beeswax. It was discovered that when the drug-loaded SLNs were mixed with egg-lecithin and Tween-80, as well as when the total surfactant concentration was increased, the average particle size of the drug-loaded SLNs decreased.
Results: The drug-loaded nanoparticles, when given in combination with bio-enhancers such as piperine and quercetin, enhanced the drug's effectiveness. The Area Under Curve (AUC) was increased when the drug was coupled with bio-enhancers. Based on the findings, it can be concluded that piperine and quercetin when used with drug-loaded nanoparticles improve their therapeutic effectiveness.
Conclusion: Bioenhancers are crucial to amplifying the bioavailability of many synthetic drugs. These attributes are useful to reduce the dose of drugs and increase the therapeutic efficacy of drugs with poor bioavailability.
[http://dx.doi.org/10.4103/0975-9476.65073] [PMID: 21836795]
[http://dx.doi.org/10.1007/978-3-642-98093-0]
[http://dx.doi.org/10.1016/B978-0-12-802147-7.00064-4]
[http://dx.doi.org/10.1007/s00228-005-0070-2]
[http://dx.doi.org/10.1177/009286159603000409]
[http://dx.doi.org/10.1100/2012/637953]
[http://dx.doi.org/10.1016/S2221-1691(13)60060-X] [PMID: 23620848]
[http://dx.doi.org/10.4172/2153-2435.1000591]
[http://dx.doi.org/10.1016/S0169-409X(97)00497-3] [PMID: 10837555]
[http://dx.doi.org/10.1016/j.ijpharm.2013.04.003] [PMID: 23598075]
[http://dx.doi.org/10.1016/j.medidd.2020.100027]
[http://dx.doi.org/10.1093/ajcn/74.4.418] [PMID: 11566638]
[http://dx.doi.org/10.1002/ptr.2899] [PMID: 19585479]
[http://dx.doi.org/10.1016/j.ijpharm.2004.12.004] [PMID: 15907592]
[http://dx.doi.org/10.1016/S0304-4017(03)00008-6] [PMID: 12623212]
[PMID: 1602384]
[http://dx.doi.org/10.1007/BF00685655] [PMID: 7923555]
[http://dx.doi.org/10.1515/DMDI.2000.17.1-4.351] [PMID: 11201303]
[http://dx.doi.org/10.1124/dmd.106.011072] [PMID: 17050652]
[http://dx.doi.org/10.4142/jvs.2005.6.3.197] [PMID: 16131821]
[http://dx.doi.org/10.1124/dmd.32.7.768] [PMID: 15205394]
[http://dx.doi.org/10.1002/bmc.1494] [PMID: 20845375]
[http://dx.doi.org/10.1016/j.phymed.2003.12.013] [PMID: 16323295]
[http://dx.doi.org/10.1146/annurev.nutr.17.1.353] [PMID: 9240932]
[http://dx.doi.org/10.1073/pnas.94.5.2031] [PMID: 9050899]
[PMID: 17598701]
[PMID: 3240714]
[http://dx.doi.org/10.1016/0005-2736(76)90160-7] [PMID: 990323]
[http://dx.doi.org/10.1248/bpb1978.12.332] [PMID: 2778626]
[http://dx.doi.org/10.1016/j.addr.2012.09.027] [PMID: 12535572]
[http://dx.doi.org/10.1016/j.matpr.2021.05.407]
[http://dx.doi.org/10.1016/j.matpr.2021.05.573]
[http://dx.doi.org/10.1080/00498254.2020.1773008] [PMID: 32432967]
[http://dx.doi.org/10.1002/ptr.6123] [PMID: 29806225]
[http://dx.doi.org/10.1016/S1875-5364(18)30041-4] [PMID: 29455730]
[http://dx.doi.org/10.1016/j.phymed.2018.09.217] [PMID: 30668388]
[http://dx.doi.org/10.1016/j.jpba.2015.06.027] [PMID: 26201645]
[http://dx.doi.org/10.1002/mnfr.201100117] [PMID: 21714124]
[http://dx.doi.org/10.1080/03639045.2020.1762201] [PMID: 32340496]
[http://dx.doi.org/10.1080/08982104.2021.1918153] [PMID: 33944662]
[http://dx.doi.org/10.1016/j.jddst.2022.103215]
[http://dx.doi.org/10.1016/S1359-6446(03)02903-9] [PMID: 14678737]
[http://dx.doi.org/10.2165/00003495-199700544-00004] [PMID: 9361956]
[http://dx.doi.org/10.1517/17425247.2015.1015985] [PMID: 25687105]
[http://dx.doi.org/10.1016/j.fitote.2010.05.001] [PMID: 20471457]
[http://dx.doi.org/10.1016/j.ijpharm.2006.04.023] [PMID: 16837151]
[PMID: 18338614]
[PMID: 18619344]
[http://dx.doi.org/10.1097/CAD.0b013e328332a322] [PMID: 19966540]
[http://dx.doi.org/10.1016/S0168-3659(99)00267-9] [PMID: 10742577]
[http://dx.doi.org/10.1016/j.colsurfb.2005.12.011] [PMID: 16480856]
[http://dx.doi.org/10.1080/02652040500099919] [PMID: 16361192]
[http://dx.doi.org/10.1007/978-0-387-77668-2_20]
[http://dx.doi.org/10.1016/S0169-409X(02)00118-7] [PMID: 12460720]
[http://dx.doi.org/10.1111/j.1742-481X.2011.00933.x] [PMID: 22296524]
[http://dx.doi.org/10.1016/S0939-6411(03)00067-5] [PMID: 12957632]
[http://dx.doi.org/10.1007/s11095-008-9791-0] [PMID: 19034626]
[http://dx.doi.org/10.1016/j.powtec.2007.08.014]
[http://dx.doi.org/10.1211/jpp.58.9.0009] [PMID: 16945181]
[http://dx.doi.org/10.4314/ijhr.v2i3.47905]
[http://dx.doi.org/10.1016/j.ijpharm.2005.10.001] [PMID: 16300915]
[http://dx.doi.org/10.1016/j.etp.2008.03.010] [PMID: 18513933]
[http://dx.doi.org/10.1016/j.ijpharm.2006.09.025] [PMID: 17112692]
[PMID: 16848325]
[http://dx.doi.org/10.1208/s12248-008-9078-8] [PMID: 19191031]
[PMID: 17048677]
[http://dx.doi.org/10.1080/08982100902722381] [PMID: 19241204]
[http://dx.doi.org/10.1016/j.jconrel.2005.04.007] [PMID: 15935505]
[http://dx.doi.org/10.3390/molecules27030781] [PMID: 35164043]
[http://dx.doi.org/10.1055/a-1338-1011] [PMID: 33434941]
[http://dx.doi.org/10.3390/antiox11020353] [PMID: 35204235]
[http://dx.doi.org/10.1016/j.tifs.2020.10.030]
[http://dx.doi.org/10.3390/ma15072388] [PMID: 35407720]
[http://dx.doi.org/10.3390/pharmaceutics14010094] [PMID: 35056990]
[http://dx.doi.org/10.1556/1646.10.2018.45] [PMID: 30792921]